In8bio
Yahoo Finance • 25 days ago
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announce... Full story
Yahoo Finance • 4 months ago
IN8bio GAAP EPS of -$0.85 beats by $0.40
* IN8bio press release [https://seekingalpha.com/pr/20297721-in8bio-reports-third-quarter-2025-financial-results-and-recent-business-highlights] (INAB [https://seekingalpha.com/symbol/INAB]): Q3 GAAP EPS of -$0.85 beats by $0.40. * As... Full story
Yahoo Finance • 4 months ago
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio Stat... Full story
Yahoo Finance • 7 months ago
IN8bio GAAP EPS of -$1.24 beats by $0.56
* IN8bio press release [https://seekingalpha.com/pr/20193937-in8bio-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:INAB [https://seekingalpha.com/symbol/INAB]): Q2 GAAP EPS of -$1.24 beats by $0.56.... Full story
Yahoo Finance • 9 months ago
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the... Full story
Yahoo Finance • 9 months ago
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, sh... Full story
Yahoo Finance • 12 months ago
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company... Full story
Yahoo Finance • 12 months ago
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded... Full story
Yahoo Finance • last year
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, main... Full story
Yahoo Finance • last year
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogenei... Full story
Yahoo Finance • last year
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS)... Full story
Yahoo Finance • 2 years ago
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort... Full story
Yahoo Finance • 2 years ago
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster NEW YORK, Nov. 10, 2023 (GLOBE NEWS... Full story
Yahoo Finance • 2 years ago
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number: 4853). Held Research & Development Day, feat... Full story
Yahoo Finance • 2 years ago
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. A treated patient, with paired tissue b... Full story
Yahoo Finance • 2 years ago
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential to produce billions of iVδ1 T cells.IN8b... Full story
Yahoo Finance • 2 years ago
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
New dataon thecompleted dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patientswith hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented... Full story
Yahoo Finance • 2 years ago
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will particip... Full story
Yahoo Finance • 2 years ago
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB... Full story
Yahoo Finance • 2 years ago
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive... Full story
